FDA 483 - Cipla, Ltd. - May 06, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Cipla Ltd., an API and Finished Dosage Manufacturer in Kurkumbh, Maharashtra, India, identified a significant lapse in their quality system. The firm failed to fully follow the responsibilities and procedures applicable to its quality control unit. Specifically, uncontrolled "SAMPLE LOCATION CHART" documents were found in use for stability samples within multiple stability chambers, indicating a failure to adhere to established document control procedures.
ID · 7c8e1395-291d-4698-ad4d-88a7bde50b11